Combination of Camrelizumab and chemotherapy and sequential radiotherapy vs camrelizumab combined with chemotherapy in the treatment of advanced oligometastatic esophageal squamous cell carcinoma-A randomized, controlled, multicenter, phase III study

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms ESCORT-1st-RT

Most Recent Events

17 Sep 2024 New source identified and integrated (ChiCTR2400079514 : Chinese Clinical Trial Register)
15 Jul 2024 New trial record
04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight